{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"51.87","upperLimit":"73.37","value":"63.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"84"}],"units":"Participants"}],"description":"Post-baseline transfusion independence (red blood cell \\[RBC\\] and platelet transfusion independence) was defined as any 56-day period after Cycle 1 Day 1 in which the participant did not receive either a RBC or platelet transfusion.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received IMGN632 via IV infusion on Day 1 of each 21-day cycle.","id":"OG000","title":"BPDCN Participants - Schedule A: IMGN632 0.045 mg/kg"}],"paramType":"NUMBER","populationDescription":"The safety population included all participants who received at least 1 dose of study drug. Here, 'Overall number of participants analyzed' = BPDCN participants. Per protocol, this endpoint evaluated only BPDCN participants, all of whom were in arm Schedule A: IMGN632 0.045 mg/kg.","reportingStatus":"POSTED","timeFrame":"Up to approximately 81 months","title":"Percentage of Participants With Post-baseline Transfusion Independence in BPDCN Participants","type":"SECONDARY","unitOfMeasure":"percentage of participants"}